Research and Trials at Southern Neurology - Southern Neurology - Sydney

Go to content
Clinical Trials and Research
As part of the comprehensive service that Southern Neurology provides, we also participate in investigator driven and industry sponsored clinical trials. This provides our patients with the opportunity to have access to potential new therapies. In general, Southern Neurology is compensated by the pharmaceutical companies on a per-subject basis for each clinical trial to cover the costs of investigator time, ancillary personnel, facilities use, tests and procedures.

Below is a list of clinical trials that we are currently or imminently involved in as part of an international multi-centre collaboration. Generally, patients who wish to take part in these trials will need to be assessed and managed by one of our Neurologists to ensure that all inclusion criteria are met for the particular trial. Please contact our clinical trials coordinator Melissa Murphy (mmurphy@southern-neurology.com.au) if you would like to find out more.

Browse the Research and related Publications by our Doctors here.

APM001: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, 60-Week, Phase II Clinical Trial of Three Re-Purposed Medications in Moderate Severity Parkinson’s Disease

  • Condition: Moderate Severity Parkinson’s Disease
  • Drug: Alogliptin 25mg QID, Albuterol 4mg BD, Nilvadipine 8mg BD, Placebo
SLT001: A Multicentre, Randomised, Double-Blind, Placebo Controlled Trial to Evaluate the Effectiveness and Safety of Sailuotong (SLT), a Standardised Chinese Herbal Medicine Formula in Patients with Vascular Dementia and Alzheimer’s Disease with Cerebrovascular Disease

  • Condition: Vascular Dementia and Alzheimer’s Disease with Cerebrovascular Disease
  • Drug: Sailuotong,
    P
    lacebo
CVL-751-PD-002: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson’s Disease (TEMPO-2 Trial)

  • Condition: Early Parkinson’s Disease
  • Drug: Tavapadon (CVL-751) 5 to 15 mg, Placebo
CVL-751-PD-003: A Phase 3, Double-Blind, Randomized, Placebo-Controlled,  Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate  CVL-751-PD-003: A Phase 3, Double-Blind, Randomized, Placebo-Controlled,  Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations (TEMPO-3 Trial)

  • Condition: Parkinson’s Disease in Levodopa-Treated Adults With Motor Fluctuations
  • Drug: Tavapadon (CVL-751) 5 to 15 mg, Placebo
MC/NBS-OBS/19: An observational study investigating and auditing the safety, tolerability and further efficacy characteristics of a pharmaceutical grade cannabis medicine (NanaBis) prescribed to eligible patients for the management of cancer related or non-cancer related pain in general and specialty medical practices  (NanaBis Observational Study)

  • Condition: Cancer related or non-cancer related pain
  • Drug: NanaBis
109MS401: Phase4: A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)

  • Condition: Relapsing Remitting Multiple Sclerosis
  • Drug: Tecfidera
GN39763: Phase 2:  A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy, and safety study of MTAU9937A in patients with prodromal to mild Alzheimer’s disease (Tauriel)

  • Condition: Alzheimer’s Disease
  • Drug: Semorinemab, Placebo
WN29922: Phase 3: A Phase III multicentre, randomised double-blind, placebo-controlled parallel-group, efficacy, and safety study of Gantenerumab in patients with early (prodromal to mild) Alzheimer’s disease (Graduate)

  • Condition: Alzheimer’s Disease
  • Drug: Gantenerumab, Placebo
Copyright 2020.
Webpage design by WillZ
2/19 Kensington St
Kogarah NSW 2217
(opposite St George Hospital)
T: 02 8566 1500
F: 02 9553 7090
Back to content